Point‐of‐care diabetes testing in the dental setting: A national scope of practice survey

Abstract

AbstractObjectivesThe aim of this study was to assess the knowledge of state dental directors regarding their state's professional practice act, specifically scope of practice laws regarding point‐of‐care chairside screening for diabetes.MethodsA cross‐sectional study design was used to examine the 50 state dental directors' knowledge of policy around point‐of‐care diabetes testing in their state. A five‐item survey instrument was designed in a web‐based platform and electronically distributed in 2022.ResultsThirty‐seven states (74%) responded to the survey. Regarding whether it was within the scope of practice for dentists to provide chairside point‐of‐care HbA1c screening, 17 states (46.0%) responded “yes,” 5 states (13.5%) responded “no,” and 15 states (40.5%) responded “don't know.” Of the 17 states who provide diabetes testing, four states (23.5%) reported that dentists were reimbursed, nine states (53.0%) reported they were not reimbursed, and four states (23.5%) reported they did not know regarding reimbursement.ConclusionsThere is significant state heterogeneity with regard to laws, regulations, and reimbursement for chairside diabetes testing in the United States. This is accompanied by vagueness and lack of specificity in the state education laws. For more widespread promotion and adoption of this evidence‐based screening, the entire dental community including clinicians, educators, policymakers, payers, and professional organizations at all levels are encouraged to work together to advocate for clarification and specificity in the language of state education laws as well as reimbursement for this vital service.